OverviewSuggest Edit

G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. It offers COSELA, a product that helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer. The company also develops trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor for patients with first-line colorectal cancer and neoadjuvant breast cancer. G1 Therapeutics also offers rintodestrant, an oral selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer.

TypePublic
Founded2008
HQDurham, NC, US
Websiteg1therapeutics.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2020)122(+18%)
Job Openings11
Revenue (FY, 2020)$45.3 M
Share Price (Sept 2021)$15.3(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at G1 Therapeutics

Mark Avagliano

Mark Avagliano

Chief Business Officer
Jennifer Moses

Jennifer Moses

Chief Financial Officer
James Stillman Hanson

James Stillman Hanson

General Counsel
Terry Murdock

Terry Murdock

Chief Operating Officer
Raj Malik

Raj Malik

Chief Medical Officer
Ostra Jewell

Ostra Jewell

Vice President, Human Resources
Show more

G1 Therapeutics Office Locations

G1 Therapeutics has an office in Durham
Durham, NC, US (HQ)
400 Park Offices Dr Suite 218
Show all (1)

G1 Therapeutics Financials and Metrics

G1 Therapeutics Revenue

G1 Therapeutics's revenue was reported to be $45.29 m in FY, 2020
USD

Revenue (Q1, 2021)

14.2m

Gross profit (Q1, 2021)

14.0m

Gross profit margin (Q1, 2021), %

98.3%

Net income (Q1, 2021)

(36.4m)

EBIT (Q1, 2021)

(25.5m)

Market capitalization (23-Sept-2021)

638.2m

Closing stock price (23-Sept-2021)

15.3

Cash (31-Mar-2021)

279.0m

EV

396.7m
G1 Therapeutics's current market capitalization is $638.2 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

45.3m

General and administrative expense

18.6m40.0m68.5m

R&D expense

70.7m89.0m73.3m

Operating expense total

89.3m129.0m141.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

2.1m26.6m14.2m

Cost of goods sold

243.0k

Gross profit

14.0m

Gross profit Margin, %

98%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

369.3m269.2m207.3m

Accounts Receivable

237.0k

Prepaid Expenses

843.0k1.7m8.8m

Current Assets

370.1m271.0m216.4m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

347.8m324.9m299.9m242.4m234.3m238.3m279.0m

Accounts Receivable

5.0m

Prepaid Expenses

1.1m3.4m3.0m1.1m5.8m7.2m11.4m

Current Assets

348.9m328.3m303.0m243.6m240.1m245.6m297.0m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(85.3m)(122.4m)(99.3m)

Depreciation and Amortization

175.0k356.0k582.0k

Accounts Payable

(1.0m)248.0k(244.0k)

Cash From Operating Activities

(74.3m)(99.6m)(83.7m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(24.0m)(54.6m)(87.0m)(31.0m)(62.2m)(73.9m)(26.4m)

Depreciation and Amortization

64.0k129.0k215.0k159.0k317.0k462.0k120.0k

Inventories

(1.4m)

Accounts Payable

(631.0k)(713.0k)2.6m992.0k(868.0k)(1.4m)(953.0k)
USDFY, 2018

Financial Leverage

1 x

P/E Ratio

(7.5)
Show all financial metrics

G1 Therapeutics Operating Metrics

FY, 2018FY, 2019FY, 2020

Patent Families

253030

Patents (US)

203140

Patents and Patent Applications

160350350
Show all operating metrics

G1 Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

G1 Therapeutics Online and Social Media Presence

Embed Graph

G1 Therapeutics News and Updates

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force

- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities - - New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -

G1 Therapeutics to Participate in Two Upcoming September Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in September.

G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for COSELA™ (trilaciclib) when a…

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021

RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET…

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combinati…
Show more

G1 Therapeutics Blogs

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights Content Import Wed, 08/04/2021 - 16:02 G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights August 4, 2021 at 4:01 PM EDT This releas…

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

RESEARCH TRIANGLE PARK, N.C. , May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4 th through 8 th .

G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights

G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights Content Import Wed, 05/05/2021 - 16:03 G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights May 5, 2021 at 4:01 PM EDT This release is …

G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 Content Import Tue, 01/05/2021 - 07:01 G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 January 5, 2021 at 7:00 AM EST …

G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020

G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020 Content Import Wed, 11/11/2020 - 07:02 G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020 November 11, 2020 at 7:01 AM EST This…

G1 Therapeutics Announces Chief Executive Officer Succession Plan

- Mark Velleca , M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors - Jack Bailey to succeed Dr. Velleca as Chief Executive Officer effective January 1, 2021 RESEARCH TRIANGLE PARK, N.C. , Sept.
Show more

G1 Therapeutics Frequently Asked Questions

  • When was G1 Therapeutics founded?

    G1 Therapeutics was founded in 2008.

  • Who are G1 Therapeutics key executives?

    G1 Therapeutics's key executives are Mark Avagliano, Jennifer Moses and James Stillman Hanson.

  • How many employees does G1 Therapeutics have?

    G1 Therapeutics has 122 employees.

  • What is G1 Therapeutics revenue?

    Latest G1 Therapeutics annual revenue is $45.3 m.

  • What is G1 Therapeutics revenue per employee?

    Latest G1 Therapeutics revenue per employee is $371.2 k.

  • Who are G1 Therapeutics competitors?

    Competitors of G1 Therapeutics include Kadmon, Zyngenia and Bluebird Bio.

  • Where is G1 Therapeutics headquarters?

    G1 Therapeutics headquarters is located at 400 Park Offices Dr Suite 218, Durham.

  • Where are G1 Therapeutics offices?

    G1 Therapeutics has an office in Durham.

  • How many offices does G1 Therapeutics have?

    G1 Therapeutics has 1 office.